For too long AD have been a too highly variable environment for clinical research!
-The patients present with highly variable conditions
-The treatments have widely different modes of action and possible targets
-The assessment measures are highly variable and subject to large errors
No wonder it has been almost impossible to pick up any indicators or signals of benefit!!!
At last – here is at the start a 8 point classification system for patients based on amyloid, tau and neurodegeneration AT(N)
It means a formal biomarker-based disease continuum replacing the 2011 idea of three stages—preclinical, mild cognitive impairment, and dementia
<<<DISEASE CLASSIFICATION NEWS>>>